2023 World Conference on Lung Cancer (Posters)-P1.23. Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer

P1.23. Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

Liquid biopsies offer a non-invasive method for testing biomarkers in non-small cell lung cancer (NSCLC) when tissue genotyping is not possible. This study compares the efficacy of LiquidHALLMARK, an amplicon-based next-generation sequencing (NGS) liquid biopsy, with tissue genotyping in detecting guideline-recommended biomarkers (G9) for NSCLC. The study included 120 treatment-naïve metastatic non-squamous NSCLC patients from multiple sites in the USA and Singapore.<br /><br />The results showed that at least one G9 biomarker was identified in 54.2% of patients by tissue genotyping and in 50.0% of patients by LiquidHALLMARK. The clinical sensitivity was 72.3% and the concordance between tissue genotyping and LiquidHALLMARK for G9 biomarkers was 93.1-100%. LiquidHALLMARK detected 74.6% of tissue-confirmed G9 biomarkers, while another NGS test called Guardant360 detected 64.2%.<br /><br />In terms of patient numbers, LiquidHALLMARK detected at least one G9 biomarker in 72.3% of patients, while Guardant360 detected at least one G9 biomarker in 66.2% of patients. Both LiquidHALLMARK and Guardant360 detected G9 biomarkers in 13 out of 55 patients with negative or insufficient tissue samples.<br /><br />Overall, the results indicate that LiquidHALLMARK identified more tissue-confirmed G9 biomarkers compared to Guardant360. The use of amplicon-based liquid biopsy technology provides an additional tool for profiling metastatic NSCLC and can complement tissue genotyping in identifying targeted therapy options for patients. <br /><br />The findings from this study contribute to the growing body of evidence supporting the use of liquid biopsies as a valuable tool in the management of lung cancer, particularly for non-squamous NSCLC patients where tissue genotyping may be challenging. Liquid biopsies offer a non-invasive and potentially more sensitive approach to identifying biomarkers and guiding targeted therapy decisions.

Asset Subtitle

Richa Dawar

Meta Tag

Speaker Richa Dawar

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

Liquid biopsies

non-invasive method

testing biomarkers

non-small cell lung cancer

NSCLC

tissue genotyping

LiquidHALLMARK

amplicon-based next-generation sequencing

clinical sensitivity

Guardant360